Monte Rosa Therapeutics, Inc. (GLUE) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 7 Buy, 2 Hold.
The consensus price target is $31.75 (low: $22.00, high: $37.00), representing an upside of 81.4% from the current price $17.50.
Analysts estimate Earnings Per Share (EPS) of $-1.25 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.98 vs est $-1.25 (beat +21.9%). 2025: actual $-0.46 vs est $-0.26 (missed -78.4%). Analyst accuracy: 64%.
GLUE Stock — 12-Month Price Forecast
$31.75
▲ +81.43% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Monte Rosa Therapeutics, Inc., the average price target is $31.75, with a high forecast of $37.00, and a low forecast of $22.00.
The average price target represents a +81.43% change from the last price of $17.50.
Highest Price Target
$37.00
Average Price Target
$31.75
Lowest Price Target
$22.00
GLUE Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Monte Rosa Therapeutics, Inc. in the past 3 months
EPS Estimates — GLUE
64%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.98
vs Est –$1.25
▲ 28.1% off
2025
Actual –$0.46
vs Est –$0.26
▼ 43.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — GLUE
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.076B
vs Est $0.060B
▲ 20.9% off
2025
Actual $0.124B
vs Est $0.136B
▼ 10.3% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
